The latest industry analysis conducted by Future Market Insights (FMI) has shed light on the burgeoning demand within the global small molecule CMO/CDMO market. According to the report, the market is estimated to be valued at approximately US$ 74,998.1 Million in 2024, with a projected Compound Annual Growth Rate (CAGR) of 5.2% over the forecast period from 2024 to 2034. This trajectory is expected to culminate in a valuation of US$ 124,532.4 Million by 2034.
Small-molecule Active Pharmaceutical Ingredients (APIs) serve as the backbone of the pharmaceutical landscape, constituting chemically synthesized compounds with low molecular weights that form the active therapeutic component of pharmaceutical products. These APIs play a crucial role in delivering the intended therapeutic effects by interacting with specific biological targets within the body.
Request a Sample copy of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-18438
The insights provided by FMI underscore the vital role played by small molecule CMO/CDMOs in the pharmaceutical sector, highlighting their significance in ensuring the availability of high-quality APIs for a wide range of therapeutic applications. The projected growth of the market signals a promising outlook for stakeholders, including manufacturers, investors, and healthcare providers, amidst evolving healthcare needs and technological advancements.
The steady rise in demand for small molecule CMO/CDMO services can be attributed to the pharmaceutical industry’s growing reliance on outsourcing for efficient and cost-effective drug development and manufacturing processes. The market’s projected CAGR signifies a sustained demand for these services, indicating a favorable outlook for industry participants.
Demand for Small-molecule API are characterized by their well-defined chemical structures, relatively simple molecular configurations, and the ability to be synthesized using established chemical processes. Pharmaceutical firms can use the knowledge and resources of outside organizations for manufacturing and development. This can help them concentrate on their core strengths, such as research and development, thanks to the outsourcing strategy.
The expansion of the biopharmaceutical pipeline means that pharmaceutical companies have a large number of drug candidates in multiple stages of development. This increasing workload can lead to resource constraints across pharmaceutical companies. This is set to promote them to seek external partners such as CMOs and CDMOs to handle aspects of drug development and manufacturing.
Different small-molecule drug candidates have unique characteristics and requirements. CMOs and CDMOs that offer specialized expertise in areas such as formulation, process optimization, and analytical testing are sought after to address the specific needs of each drug candidate.
With more drug candidates in the pipeline, pharmaceutical companies are under pressure to accelerate development timelines to bring promising drugs to market sooner. Outsourcing to CMOs and CDMOs can help streamline development processes and expedite time-to-market.
A growing pipeline often leads to the need for global market expansion. CMOs and CDMOs with global manufacturing capabilities can support pharmaceutical companies in reaching new markets and ensuring consistent supply. Moreover, outsourcing to CMOs and CDMOs provides access to their innovative technologies, advanced manufacturing processes, and formulation expertise, contributing to the successful development of novel drug candidates.
Key Takeaways from the Small Molecule CMO/CDMO Market Study:
- By product, the standard API segment held a lucrative small molecule CMO/CDMO market share of 7% in 2023.
- By service, the process development segment is expected to hold over 8% market value share by the end of 2034.
- By company size, the mid-sized company segment is set to progress at a 8% CAGR, totaling a valuation of US$ 55,615.8 million by 2033.
- By the scale of operation, the commercial segment is set to expand at a high CAGR of 6%, totaling US$ 90,027.3 million in 2033.
- East Asia is considered the leading region, with a value share of 0% at the end of the forecast period.
Get Exclusive Purchase Now to Access Market Trends: https://www.futuremarketinsights.com/checkout/18438
Competitive Landscape:
Acquisition and expansion among leading companies or brands is the key strategy of renowned manufacturers in the global small molecule CMO/CDMO market. Companies such as Ajinomoto Bio-Pharma Services and Asymchem are aiming to enhance their presence in the market and compete with other players during the estimated years.
Key Companies Profiled:
- Pfizer CentreOne
- Baxter BioPharma Solutions
- Catalent
- Lonza
- Syngene International
- Boehringer Ingelheim
- Piramal Pharma Solutions
- Wuxi AppTec
- Patheon (Thermo Fisher Scientific Inc.)
- Adare Pharma Solutions
- Ajinomoto Bio-Pharma Services
- Ascendia Pharma
- Asymchem
- August Bioservices
- Cambrex
- Nanoform
- PCI Pharma Services
- Quotient Sciences
- Societal™ CDMO
- Siegfried Holding AG
- Corden Pharma International
Following are a handful of examples of acquisitions made by them to be at the top position:
- In August 2020, Ajinomoto Bio-Pharma Services added a new 8,500-square-meter production facility to its Visakhapatnam, India site, increasing its capability for manufacturing small molecules.
- In November 2022, Snapdragon Chemistry, a United States-based chemical technology company that offers experience in continuous manufacturing and early-stage chemical process development services to the pharmaceutical and fine chemical industries, was acquired by Asymchem. It is a contract development and manufacturing organization (CDMO) catering to the global pharmaceutical and biotech industry.
Request Report Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-18438
Key Market Segments Covered in Small Molecule CMO/CDMO Industry Research:
By Product:
- Standard API
- HPAPI
By Service:
- Process Development
- Analytical Method Development
- GMP Manufacturing Service
- Scale-Up and Tech Transfer
- Quality Control and Quality Assurance
- Regulatory Assistance
- Technology and Innovation
By Company Size:
- Large
- Mid-sized
- Small
By Scale of Operation:
- Clinical
- Phase I
- Phase II
- Phase III
- Commercial
By Region:
- North America
- East Asia
- Western Europe
- Eastern Europe
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain:
Small Molecule API Market Size: The market is expected to generate US$ 116 billion in 2023. Small molecule API market revenue is expected to reach US$ 174 billion by 2033. A CAGR of 4.1% is expected for the small molecule API market during the forecast period.
RNA-Targeted Small Molecules Market Share: According to the latest research by Future Market Insights, RNA-Targeted Small Molecules market is set to witness a 6.6% growth during the year 2021-2031.
Small-Molecule Injectable Market Demand: The market is estimated to capture a valuation of US$ 65.10 billion in 2023 and is projected to reach US$ 131.70 billion by 2033. The market is estimated to secure a CAGR of 7.3% during the forecast period.
Small molecule-drug conjugates Market Growth: According to Future Market Insights (FMI), analysis in a recent market survey estimated that the global small molecule-drug conjugates market is expected to reach US$ 3.65 Billion by 2033 at a CAGR of 17.5%.
Small Molecule Innovator CDMO Market Outlook: The market size is projected to be valued at US$ 48.09 billion in 2023 and is expected to rise to US$ 89.43 billion by 2033. The sales of small molecule innovator CDMO are expected to grow at a significant CAGR of 6.4% during the forecast period.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
